Immutep Expands Part B of TACTI-002 Study
March 05, 2021 08:00 ET
|
Immutep Limited
Sydney, AUSTRALIA, March 05, 2021 (GLOBE NEWSWIRE) -- – Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases,...
Immutep Announces Advancement Of Phase II Trial For Eftilagimod Alpha In Covid-19 Patients To Randomised Portion Of The Study
January 27, 2021 08:00 ET
|
Immutep Limited
Independently reviewed safety run-in data prompts recommendation to initiate enrolment for the randomised portion of the Phase II EAT COVID studyUp to 110 COVID-19 patients to participate in...
Immutep Quarterly Activities Report
January 21, 2021 18:03 ET
|
Immutep Limited
Highlights Encouraging efti data reported from phase IIb AIPAC and phase II TACTI-002 clinical trialsTACTI-002 study expanded in lung cancerNew phase II trial in head and neck cancer announcedEOC...
Ulcerative Colitis Phase II Study of GSK2831781 Discontinued
January 21, 2021 17:40 ET
|
Immutep Limited
Sydney, AUSTRALIA, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study
January 06, 2021 19:04 ET
|
Immutep Limited
Completes recruitment of patients with 2nd line head and neck squamous cell carcinoma (HNSCC)Recruitment of additional 1st line non small cell lung cancer (NSCLC) patients startedFurther interim data...
Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor
December 29, 2020 16:54 ET
|
Immutep Limited
Sydney, AUSTRALIA, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...
Immutep Upscales Efti Manufacturing
December 16, 2020 08:00 ET
|
Immutep Limited
Sydney, AUSTRALIA, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
Immutep Operational Update
December 15, 2020 08:00 ET
|
Immutep Limited
Efti clinical trial status updatesExcellent financial position following recent US$7.7 million warrant exercise, with cash runway extended beyond end of calendar year 2022 Sydney, AUSTRALIA, Dec. ...
Immutep’s Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study
December 09, 2020 17:53 ET
|
Immutep Limited
New randomised, double-blind, placebo-controlled phase II clinical study to commence in Q1 CY2021Evaluates the efficacy and safety of eftilagimod alpha in combination with paclitaxel chemotherapy,...
Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer
December 09, 2020 17:14 ET
|
Immutep Limited
First time an antigen presenting cell (APC) activator has shown an Overall Survival (OS) benefit in a randomised setting in metastatic breast cancer patients known to be insensitive to immune...